Loss of insulin signaling may contribute to atrial fibrillation and atrial electrical remodeling in type 1 diabetes

胰岛素信号传导丧失可能导致1型糖尿病患者出现心房颤动和心房电重构。

阅读:1

Abstract

Atrial fibrillation (AF) is prevalent in diabetes mellitus (DM); however, the basis for this is unknown. This study investigated AF susceptibility and atrial electrophysiology in type 1 diabetic Akita mice using in vivo intracardiac electrophysiology, high-resolution optical mapping in atrial preparations, and patch clamping in isolated atrial myocytes. qPCR and western blotting were used to assess ion channel expression. Akita mice were highly susceptible to AF in association with increased P-wave duration and slowed atrial conduction velocity. In a second model of type 1 DM, mice treated with streptozotocin (STZ) showed a similar increase in susceptibility to AF. Chronic insulin treatment reduced susceptibility and duration of AF and shortened P-wave duration in Akita mice. Atrial action potential (AP) morphology was altered in Akita mice due to a reduction in upstroke velocity and increases in AP duration. In Akita mice, atrial Na(+) current (I(Na)) and repolarizing K(+) current (I(K)) carried by voltage gated K(+) (K(v)1.5) channels were reduced. The reduction in I(Na) occurred in association with reduced expression of SCN5a and voltage gated Na(+) (Na(V)1.5) channels as well as a shift in I(Na) activation kinetics. Insulin potently and selectively increased I(Na) in Akita mice without affecting I(K) Chronic insulin treatment increased I(Na) in association with increased expression of Na(V)1.5. Acute insulin also increased I(Na), although to a smaller extent, due to enhanced insulin signaling via phosphatidylinositol 3,4,5-triphosphate (PIP(3)). Our study reveals a critical, selective role for insulin in regulating atrial I(Na), which impacts susceptibility to AF in type 1 DM.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。